Purpose: Chromosomal microarray (CMA) testing provides the highest diagnostic yield for clinical testing of patients with developmental delay (DD), intellectual disability (ID), multiple congenital ...

The 2010 consensus statement on diagnostic chromosomal microarray (CMA) testing recommended an array resolution ≥400 kb throughout the genome as a balance of analytical and clinical sensitivity. In ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of ...

Microarray based comparative genomic hybridisation (array CGH) is a new technology with uses developing in various diagnostic areas within the NHS. One important context is the investigation of ...